One ricochet of the ivonescimab bullet
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
Two oncology floats to end the summer break
Bicara and DualityBio will soon test market appetite for new oncology issues.
Merck shuffles the Kelun deck again
Claudin18.2 is out, but the US big pharma opts in to a new project.
Just how independent is Genentech?
Questions continue to swirl as the unit mulls another oncology makeover.
CD19 is worth $700m to Merck
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
Agenus looks to new deals and an ex-US path
But there are no hard facts, and a Ligand obligation clouds future licensing economics.
